Compare Summit Therapeutics Inc (SMMT) vs Zillow Group Inc Class A (ZG) Price & Performance

Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.

The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.

Zillow Group (ZG) trades at $33.03, down 6.48% in the last session, with technical indicators showing a bearish trend as the price approaches key support near $32. Fundamentally, the company shows improving revenue growth to $2.58 billion in 2025 and a return to profitability with net income of $23 million, though valuation remains elevated with a P/E of 143.57. Recent news highlights Zillow's strategic shift to an integrated transaction platform and resolution of FTC litigation.

The outlook is mixed: analyst consensus targets $47.56 (44% upside) with 47% buy ratings, but near-term housing market softness and high valuation pose risks. The stock offers growth potential through platform monetization, yet investors face execution risks and macroeconomic headwinds in the real estate sector.